The programme will run until the end of 2022. Your project must be designed to ensure that the medicine will be made available to the Swiss population via the possible channels set out in the Therapeutic Products Act by the end of 2022. Milestones that are only reached after the end of 2022 due to delays will not be remunerated.
You must also submit a final report by the end of 2022. The final payment will be triggered once the final report has been reviewed.